KalVista Pharmaceuticals (KALV) Competitors

KalVista Pharmaceuticals (NASDAQ:KALV) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Which has better earnings and valuation, KALV or EVO?

Evotec has higher revenue and earnings than KalVista Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	N/A	N/A	-$126.64M	-$3.64	-2.28
Evotec	$845.74M	1.72	-$90.82M	N/A	N/A

Is KALV or EVO more profitable?

Evotec's return on equity of 0.00% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-103.92%	-88.06%
Evotec	N/A	N/A	N/A

Does the MarketBeat Community favor KALV or EVO?

KalVista Pharmaceuticals received 336 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 74.67% of users gave KalVista Pharmaceuticals an outperform vote while only 54.55% of users gave Evotec an outperform vote.

Company	Underperform	Outperform
KalVista Pharmaceuticals	Outperform Votes 342 74.67%	Underperform Votes 116 25.33%
Evotec	Outperform Votes 6 54.55%	Underperform Votes 5 45.45%

Do analysts rate KALV or EVO?

KalVista Pharmaceuticals currently has a consensus price target of $25.00, suggesting a potential upside of 201.20%. Evotec has a consensus price target of $5.93, suggesting a potential upside of 44.36%. Given KalVista Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe KalVista Pharmaceuticals is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Do insiders and institutionals hold more shares of KALV or EVO?

5.8% of Evotec shares are owned by institutional investors. 10.5% of KalVista Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more volatility & risk, KALV or EVO?

KalVista Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Does the media refer more to KALV or EVO?

In the previous week, Evotec had 3 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 4 mentions for Evotec and 1 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 1.78 beat Evotec's score of 0.92 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Evotec	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

KalVista Pharmaceuticals and Evotec tied by winning 7 of the 14 factors compared between the two stocks.